논문 상세보기

생화학분자생물학회(구 한국생화학분자생물학회)> BMB Reports> Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity

KCI등재SCISCOUPUS

Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity

Pedram Yadollahi , You-kyoung Jeon , Wooi Loon Ng , Inhak Choi
  • : 생화학분자생물학회(구 한국생화학분자생물학회)
  • : BMB Reports 54권1호
  • : 연속간행물
  • : 2021년 01월
  • : 12-20(9pages)

DOI


목차

INTRODUCTION
REGULATION OF PD-L1 EXPRESSION
INTRINSIC ACTIVITY OF PD-L1
ACKNOWLEDGEMENTS
CONFLICTS OF INTEREST
REFERENCES

키워드 보기


초록 보기

In the last decade, we have witnessed an unprecedented clinical success in cancer immunotherapies targeting the programmed cell-death ligand 1 (PD-L1) and programmed cell-death 1 (PD-1) pathway. Besides the fact that PD-L1 plays a key role in immune regulation in tumor microenvironment, recently a plethora of reports has suggested a new perspective of non-immunological functions of PD-L1 in the regulation of cancer intrinsic activities including mesenchymal transition, glucose and lipid metabolism, stemness, and autophagy. Here we review the current understanding on the regulation of expression and intrinsic protumoral activity of cancer-intrinsic PD-L1. [BMB Reports 2021; 54(1): 12-20]

UCI(KEPA)

간행물정보

  • : 자연과학분야  > 화학
  • : KCI등재
  • : SCI,SCOPUS
  • : 월간
  • : 1976-6696
  • :
  • : 학술지
  • : 연속간행물
  • : 1968-2021
  • : 4502


저작권 안내

한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.

이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.

발행기관 최신논문
| | | | 다운로드

1Cancer immunotherapy: special issue of BMB Reports in 2021

저자 : Eui-cheol Shin

발행기관 : 생화학분자생물학회(구 한국생화학분자생물학회) 간행물 : BMB Reports 54권 1호 발행 연도 : 2021 페이지 : pp. 1-1 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

2Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy

저자 : Hyung-seung Jin , Yoon Park

발행기관 : 생화학분자생물학회(구 한국생화학분자생물학회) 간행물 : BMB Reports 54권 1호 발행 연도 : 2021 페이지 : pp. 2-11 (10 pages)

다운로드

(기관인증 필요)

초록보기

Antibody-based therapeutics targeting the inhibitory receptors PD-1, PD-L1, or CTLA-4 have shown remarkable clinical progress on several cancers. However, most patients do not benefit from these therapies. Thus, many efforts are being made to identify new immune checkpoint receptor-ligand pathways that are alternative targets for cancer immunotherapies. Nectin and nectin-like molecules are widely expressed on several types of tumor cells and play regulatory roles in T- and NK-cell functions. TIGIT, CD226, CD96 and CD112R on lymphoid cells are a group of immunoglobulin superfamily receptors that interact with Nectin and nectin-like molecules with different affinities. These receptors transmit activating or inhibitory signals upon binding their cognate ligands to the immune cells. The integrated signals formed by their complex interactions contribute to regulating immune-cell functions. Several clinical trials are currently evaluating the efficacy of anti-TIGIT and anti-CD112R blockades for treating patients with solid tumors. However, many questions still need to be answered in order to fully understand the dynamics and functions of these receptor networks. This review addresses the rationale behind targeting TIGIT, CD226, CD96, and CD112R to regulate T- and NK-cell functions and discusses their potential application in cancer immunotherapy. [BMB Reports 2021; 54(1): 2-11]

3Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity

저자 : Pedram Yadollahi , You-kyoung Jeon , Wooi Loon Ng , Inhak Choi

발행기관 : 생화학분자생물학회(구 한국생화학분자생물학회) 간행물 : BMB Reports 54권 1호 발행 연도 : 2021 페이지 : pp. 12-20 (9 pages)

다운로드

(기관인증 필요)

초록보기

In the last decade, we have witnessed an unprecedented clinical success in cancer immunotherapies targeting the programmed cell-death ligand 1 (PD-L1) and programmed cell-death 1 (PD-1) pathway. Besides the fact that PD-L1 plays a key role in immune regulation in tumor microenvironment, recently a plethora of reports has suggested a new perspective of non-immunological functions of PD-L1 in the regulation of cancer intrinsic activities including mesenchymal transition, glucose and lipid metabolism, stemness, and autophagy. Here we review the current understanding on the regulation of expression and intrinsic protumoral activity of cancer-intrinsic PD-L1. [BMB Reports 2021; 54(1): 12-20]

4Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7

저자 : Ji-hae Kim , Kun-joo Lee , Seung-woo Lee

발행기관 : 생화학분자생물학회(구 한국생화학분자생물학회) 간행물 : BMB Reports 54권 1호 발행 연도 : 2021 페이지 : pp. 21-30 (10 pages)

다운로드

(기관인증 필요)

초록보기

Clinical trials have demonstrated that an increased number of effector cells, especially tumor-specific T cells, is positively linked with patients' prognosis. Although the discovery of checkpoint inhibitors (CPIs) has led to encouraging progress in cancer immunotherapy, the lack of either T cells or targets for CPIs is a limitation for patients with poor prognosis. Since interleukin (IL)-2 and IL-7 are cytokines that target many aspects of T-cell responses, they have been used to treat cancers. In this review, we focus on the basic biology of how these cytokines regulate T-cell response and on the clinical trials using the cytokines against cancer. Further, we introduce several recent studies that aim to improve cytokines' biological activities and find the strategy for combination with other therapeutics. [BMB Reports 2021; 54(1): 21-30]

5The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets

저자 : Chae Won Kim , Kyun-do Kim , Heung Kyu Lee

발행기관 : 생화학분자생물학회(구 한국생화학분자생물학회) 간행물 : BMB Reports 54권 1호 발행 연도 : 2021 페이지 : pp. 31-43 (13 pages)

다운로드

(기관인증 필요)

초록보기

Dendritic cells (DC), which consist of several different subsets, specialize in antigen presentation and are critical for mediating the innate and adaptive immune responses. DC subsets can be classified into conventional, plasmacytoid, and monocyte-derived DC in the tumor microenvironment, and each subset plays a different role. Because of the role of intratumoral DCs in initiating antitumor immune responses with tumor-derived antigen presentation to T cells, DCs have been targeted in the treatment of cancer. By regulating the functionality of DCs, several DC-based immunotherapies have been developed, including administration of tumor-derived antigens and DC vaccines. In addition, DCs participate in the mechanisms of classical cancer therapies, such as radiation therapy and chemotherapy. Thus, regulating DCs is also important in improving current cancer therapies. Here, we will discuss the role of each DC subset in antitumor immune responses, and the current status of DC-related cancer therapies. [BMB Reports 2021; 54(1): 31-43]

6Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors

저자 : Nayoung Kim , Dong-hee Lee , Woo Seon Choi , Eunbi Yi , Hyojeong Kim , Jung Min Kim , Hyung-seung Jin , Hun Sik Kim

발행기관 : 생화학분자생물학회(구 한국생화학분자생물학회) 간행물 : BMB Reports 54권 1호 발행 연도 : 2021 페이지 : pp. 44-58 (15 pages)

다운로드

(기관인증 필요)

초록보기

Natural killer (NK) cells, key antitumor effectors of the innate immune system, are endowed with the unique ability to spontaneously eliminate cells undergoing a neoplastic transformation. Given their broad reactivity against diverse types of cancer and close association with cancer prognosis, NK cells have gained considerable attention as a promising therapeutic target for cancer immunotherapy. NK cell-based therapies have demonstrated favorable clinical efficacies in several hematological malignancies but limited success in solid tumors, thus highlighting the need to develop new therapeutic strategies to restore and optimize anti-tumor activity while preventing tumor immune escape. The current therapeutic modalities yielding encouraging results in clinical trials include the blockade of immune checkpoint receptors to overcome the immune-evasion mechanism used by tumors and the incorporation of tumor-directed chimeric antigen receptors to enhance NK cell anti-tumor specificity and activity. These observations, together with recent advances in the understanding of NK cell activation within the tumor microenvironment, will facilitate the optimal design of NK cell-based therapy against a broad range of cancers and, more desirably, refractory cancers. [BMB Reports 2021; 54(1): 44-58]

7Genome editing of immune cells using CRISPR/Cas9

저자 : Segi Kim , Cedric Hupperetz , Seongjoon Lim , Chan Hyuk Kim

발행기관 : 생화학분자생물학회(구 한국생화학분자생물학회) 간행물 : BMB Reports 54권 1호 발행 연도 : 2021 페이지 : pp. 59-69 (11 pages)

다운로드

(기관인증 필요)

초록보기

The ability to read, write, and edit genomic information in living organisms can have a profound impact on research, health, economic, and environmental issues. The CRISPR/Cas system, recently discovered as an adaptive immune system in prokaryotes, has revolutionized the ease and throughput of genome editing in mammalian cells and has proved itself indispensable to the engineering of immune cells and identification of novel immune mechanisms. In this review, we summarize the CRISPR/Cas9 system and the history of its discovery and optimization. We then focus on engineering T cells and other types of immune cells, with emphasis on therapeutic applications. Last, we describe the different modifications of Cas9 and their recent applications in the genome-wide screening of immune cells. [BMB Reports 2021; 54(1): 59-69]

8Update of early phase clinical trials in cancer immunotherapy

저자 : Dae Ho Lee

발행기관 : 생화학분자생물학회(구 한국생화학분자생물학회) 간행물 : BMB Reports 54권 1호 발행 연도 : 2021 페이지 : pp. 70-88 (19 pages)

다운로드

(기관인증 필요)

초록보기

Immunotherapy has revolutionized the landscape of cancer treatment and become a standard pillar of the treatment. The two main drivers, immune checkpoint inhibitors and chimeric antigen receptor T cells, contributed to this unprecedented success. However, despite the striking clinical improvements, most patients still suffer from disease progression because of the evolution of primary or acquired resistance. This mini-review summarizes new treatment options including novel targets and interesting combinational approaches to increase our understanding of the mechanisms of the action of and resistance to immunotherapy, to expand our knowledge of advances in biomarker and therapeutics development, and to help to find the most appropriate option or a way of overcoming the resistance for cancer patients. [BMB Reports 2021; 54(1): 70-88]

1
주제별 간행물
간행물명 수록권호

KCI등재 SCI SCOUPUS

BMB Reports
54권 4호 ~ 54권 4호

KCI등재

한국분무공학회지(구 한국액체미립화학회지)
26권 1호 ~ 26권 1호

KCI등재 SCOUPUS

Mass Spectrometry Letters
12권 1호 ~ 12권 1호

KCI등재 SCI SCOUPUS

BMB Reports
54권 3호 ~ 54권 3호

KCI등재 SCI SCOUPUS

BMB Reports
54권 2호 ~ 54권 2호

KCI등재

한국분무공학회지(구 한국액체미립화학회지)
25권 4호 ~ 25권 4호

KCI등재 SCI SCOUPUS

BMB Reports
54권 1호 ~ 54권 1호

KCI등재 SCOUPUS

Mass Spectrometry Letters
11권 4호 ~ 11권 4호

KCI등재 SCI SCOUPUS

BMB Reports
53권 12호 ~ 53권 12호

KCI등재

한국분무공학회지(구 한국액체미립화학회지)
25권 3호 ~ 25권 3호

KCI등재 SCI SCOUPUS

BMB Reports
53권 11호 ~ 53권 11호

KCI등재 SCI SCOUPUS

BMB Reports
53권 10호 ~ 53권 10호

KCI등재 SCOUPUS

Mass Spectrometry Letters
11권 3호 ~ 11권 3호

KCI등재 SCI SCOUPUS

BMB Reports
53권 9호 ~ 53권 9호

KCI등재 SCI SCOUPUS

BMB Reports
53권 8호 ~ 53권 8호

KCI등재 SCOUPUS

Mass Spectrometry Letters
11권 2호 ~ 11권 2호

KCI등재 SCI SCOUPUS

BMB Reports
53권 7호 ~ 53권 7호

KCI등재

한국분무공학회지(구 한국액체미립화학회지)
25권 2호 ~ 25권 2호

KCI등재 SCI SCOUPUS

BMB Reports
53권 6호 ~ 53권 6호

KCI등재 SCI SCOUPUS

BMB Reports
53권 5호 ~ 53권 5호
발행기관 최신논문
자료제공: 네이버학술정보
발행기관 최신논문
자료제공: 네이버학술정보

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기